<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04090866</url>
  </required_header>
  <id_info>
    <org_study_id>2019-0286</org_study_id>
    <secondary_id>A534285</secondary_id>
    <secondary_id>SMPH/MEDICINE/MEDICINE*P</secondary_id>
    <secondary_id>Protocol Version 8/2/2019</secondary_id>
    <nct_id>NCT04090866</nct_id>
  </id_info>
  <brief_title>Cardiac Metabolic Remodeling After Pulmonary Vasodilator Therapy in Pulmonary Arterial Hypertension: A Pilot Study</brief_title>
  <official_title>Cardiac Metabolic Remodeling After Pulmonary Vasodilator Therapy in Pulmonary Arterial Hypertension: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary arterial hypertension(PAH) is associated with the development of right heart
      failure. In the setting of heart failure, the heart shifts to increasing dependence on
      glucose metabolism. In this study, the investigators will perform cardiac positron emission
      tomography/magnetic resonance imaging (PET/MRI) scans to measure glucose metabolism in the
      heart before and after initiation of pulmonary vasodilator therapy for pulmonary arterial
      hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary arterial hypertension is associated with the development of right heart failure. In
      the setting of heart failure, the heart shifts to increasing dependence on glucose
      metabolism. In this study, the investigators will perform cardiac positron emission
      tomography/magnetic resonance imaging (PET/MRI) scans to measure glucose metabolism in the
      heart before and after initiation of pulmonary vasodilator therapy for pulmonary arterial
      hypertension. By utilizing a rest-exercise protocol and continuous PET imaging acquisition,
      we can capture real-time changes in glucose uptake in the heart in response to acute
      exercise. By coupling these measures of dynamic glucose utilization with MRI-based cardiac
      function, we will determine cardiac metabolic efficiency.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI and sponsor will re-open study at new institution, will not transfer data due to COVID-19
    situation
  </why_stopped>
  <start_date type="Actual">November 14, 2019</start_date>
  <completion_date type="Actual">July 21, 2020</completion_date>
  <primary_completion_date type="Actual">July 21, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Ability to augment glucose uptake (&quot;substrate flexibility&quot;), defined as change in rate of glucose uptake from rest to exercise</measure>
    <time_frame>6 months</time_frame>
    <description>Substrate flexibility is defined as the change in myocardial to blood pool glucose uptake rate from rest to exercise.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in substrate flexibility after initiation of pulmonary vasodilator therapy</measure>
    <time_frame>6 months</time_frame>
    <description>Substrate flexibility is defined as the change in myocardial to blood pool glucose uptake rate from rest to exercise. Substrate flexibility before and after pulmonary vasodilator therapy will be compared.</description>
  </secondary_outcome>
  <enrollment type="Actual">2</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <condition>Right-Sided Heart Failure</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PET/MRI</intervention_name>
    <description>Positron Emission Tomograph/Magnetic Resonance Imaging - participants will undergo PET/MRI prior to initiation of pulmonary vasodilator therapy and again 4-6 months after initiation of therapy</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with IPAH or CTD-PAH
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  World Health Organization(WHO) group PAH secondary into idiopathic pulmonary arterial
             hypertension(IPAH) or connective tissue disease associated pulmonary arterial
             hypertension (CTDPAH)

          -  New York Heart Association (NYHA) classification I - III heart failure

          -  Vasodilator therapy naive

          -  Able to provide informed consent

        Exclusion Criteria:

          -  Metabolic disorders such as uncontrolled diabetes (A1c &gt; 8%) that may interfere with
             FDG uptake

          -  Baseline 6-minute walk distance (6MWD) &lt; 400 feet or NYHA class IV heart failure

          -  Musculoskeletal abnormalities that would prevent exercise

          -  Contraindications to MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kara Goss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin-Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 12, 2019</study_first_submitted>
  <study_first_submitted_qc>September 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2019</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pulmonary arterial hypertension</keyword>
  <keyword>right-sided heart failure</keyword>
  <keyword>metabolism</keyword>
  <keyword>PET/MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Dextrocardia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

